3.11
+0.235(+8.17%)
Currency In USD
| Previous Close | 2.88 |
| Open | 2.85 |
| Day High | 3.19 |
| Day Low | 2.85 |
| 52-Week High | 11.2 |
| 52-Week Low | 1.61 |
| Volume | 795,230 |
| Average Volume | 1.29M |
| Market Cap | 199.13M |
| PE | -2.06 |
| EPS | -1.51 |
| Moving Average 50 Days | 2.46 |
| Moving Average 200 Days | 4.21 |
| Change | 0.24 |
If you invested $1000 in Larimar Therapeutics, Inc. (LRMR) 10 years ago, it would be worth $7.37 as of July 03, 2025 at a share price of $3.11. Whereas If you bought $1000 worth of Larimar Therapeutics, Inc. (LRMR) shares 5 years ago, it would be worth $263.56 as of July 03, 2025 at a share price of $3.11.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Larimar Therapeutics Announces FDA Recommendations on Safety Database, and Other Details of Nomlabofusp BLA Submission for Friedreich’s Ataxia Program
GlobeNewswire Inc.
Jun 23, 2025 11:00 AM GMT
Interactions with FDA over the past year have provided clear expectations for the path to submission of the nomlabofusp BLAWritten FDA recommendations for safety database include a total of at least 30 participants with continuous exposure for 6 mont
Larimar Therapeutics Announces Regulatory Update Call on the Nomlabofusp Program for the Treatment of Friedreich’s Ataxia
GlobeNewswire Inc.
Jun 20, 2025 8:05 PM GMT
Conference call and webcast on Monday, June 23, 2025 at 8:00 am EDTBALA CYNWYD, Pa., June 20, 2025 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (Larimar) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for
Larimar Therapeutics to Present at the Leerink Partners Global Healthcare Conference
GlobeNewswire Inc.
Mar 03, 2025 9:05 PM GMT
BALA CYNWYD, Pa., March 03, 2025 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (Larimar) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced that members of the company